Revatio is Food and Drug Administration (FDA)–approved to treat pulmonary arterial hypertension (PAH). PAH is a condition where there is increased pressure in the arteries of the lungs.

Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in adults who are temporarily unable to take oral Revatio. Give by IV bolus injection.

An attempt by Pfizer to extend the uses of its pulmonary artery hypertension (PAH) drug Revatio into a new paediatric indication has had a major setback. Revatio (sildenafil citrate ...

has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20mg. Sildenafil is the generic equivalent of Pfizer’s Revatio, which is indicated ...